Drug Trial Radar · NCT05607498
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 1, 2023
Primary completion
Oct 31, 2025
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- EpimAb Biotherapeutics (Suzhou)Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.
Conditions
- Advanced/Metastatic Solid Tumors
- Relapse/Refractory Lymphoma
Interventions
EMB07Drug
EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events as assessed by CTCAE V5.0.Time frame: Screening up to 30 days after the last dose.
- Incidence of serious adverse events (SAE).Time frame: Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.
- Incidence of dose interruptions.Time frame: Screening up to 30 days after the last dose.
- Dose intensity.Time frame: Screening up to 30 days after the last dose.
- The incidence of DLTs during the first cycle of treatment.Time frame: First infusion to the end of cycle 1. (each cycle is 28 days).
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia · Recruiting
One Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Affiliated Hospital of Hebei University
Baoding, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, China · Recruiting
The Affiliated Tumour Hospital of Harbin Medical University
Harbin, China · Recruiting
Shandong Cancer Hospital
Shandong, China · Recruiting
Tianjin Medical University Cancer Institue & Hospital
Tianjin, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.